CMS Proposes 15% Annual Medicare Lab Fee Cuts, Threatening Quest and Labcorp Revenue

The Centers for Medicare & Medicaid Services (CMS) plans to reduce reimbursement rates for clinical laboratory tests by up to 15% annually, beginning January 1, 2027. The proposed changes, detailed in the preliminary Calendar Year 2027 Clinical Laboratory Fee Schedule (CLFS) released Monday, represent a significant earnings risk for industry leaders Quest Diagnostics (NYSE:DGX) and Labcorp (NYSE:LH).

Details of the Proposed Cuts

CMS disclosed that it has been overpaying laboratories by approximately 16% compared to private insurers for the same services. The agency aims to close this gap, estimating the rate realignment will save taxpayers around $1 billion annually, according to a press release.

"Taxpayers and Medicare patients have been paying excessive rates to labs for years," CMS Administrator Dr. Mehmet Oz said in the release. He added that the agency is working to ensure Medicare pays market rates. The new preliminary rates are based on data from 6,411 laboratories, a much broader sample than in previous years. By law, the payment reductions are capped at 15% per year through 2029, meaning the full impact will be phased in over several years.

Market Impact on Lab Giants

The announcement presents the clearest Medicare-related earnings threat that Quest and Labcorp have faced in years, as both companies derive a substantial portion of their revenue from routine testing reimbursed under the CLFS.

While the companies have not disclosed the exact percentage of revenue exposed to these specific cuts, analysts have offered initial projections:

Ad

• Every 5-percentage-point reduction in CLFS rates is estimated to translate into a roughly 1-2% headwind to earnings per share (EPS) for both DGX and LH.
• A full 15% first-year reduction therefore implies a potential EPS drag of approximately 3-6% for each company, before any offsetting factors.

Revised sell-side estimates are not expected until CMS finalizes the rates, which is scheduled for November 2026.

Industry Response and Next Steps

The clinical laboratory industry is actively lobbying Congress to prevent the cuts from taking effect. Quest Diagnostics and the American Clinical Laboratory Association (ACLA) are advocating for the passage of the RESULTS Act, a bipartisan bill aimed at reforming the rate-setting process.

Ahead of the CMS announcement, Quest published a national survey on September 16 indicating that a majority of voters are concerned the cuts could harm patient access to testing. "When access to reliable, innovative testing is at risk, they and their families are the ones who will pay the price," said Dr. Lee H. Hilborne, Senior National Medical Director at Quest Diagnostics.

The public has until approximately October 21, 2026, to comment on the preliminary rates. Without congressional intervention, the final rates published in November will be locked in for the January 1, 2027, start date.